Helsinn Group supports Satellite Symposium at 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it is supporting a satellite symposium hosted by The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), entitled: 'Navigating cancer anorexia-cachexia: the modified Glasgow Prognostic Score in the spotlight', at the 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting.

This educational event hosted by SCWD will focus on and explain diagnostic methods and the practical solutions to cancer cachexia. The audience will be made up of oncologists, cardiologists, gerontologists, palliative care specialists, primary care physicians and nurses, the groups that on a day to day basis have to treat these debilitating conditions associated with cancer.

This symposium brings together a panel of world-renowned experts in cachexia, sarcopenia, and muscle wasting. The event will be chaired by Maurizio Muscaritoli, MD, Director of the Clinical Nutrition Management Unit, Sapienza University of Rome, Rome, Italy and the panel members comprises Donald McMillan, PhD, Professor of Surgical Science, University of Glasgow, Glasgow, UK and Barry Laird, MD, Senior Clinical Lecturer in Palliative Medicine, University of Edinburgh, Edinburgh, UK.

The symposium will be held on Friday, 8th December 2017 at 13:15 - 14:15 in the Sheraton Roma Hotel & Conference Centre, Rome, Italy. Below the programme:
 


Switching on the navigation system: welcome and introduction


By Professor Maurizio Muscaritoli (Italy)
 


Blazing the trial: cancer anorexia-cachexia identification using the modified Glasgow Prognostic Score


By Professor Donald McMillan (UK)
 


Plotting the course: modified Glasgow Prognostic Score subgroup analysis in the ROMANA trials and beyond


By Dr Barry Laird (UK)
 


The road ahead: summary and close of meeting


By Professor Maurizio Muscaritoli (Italy)

Silvia Sebastiani, Head of Medical Affairs, commented: "Helsinn remains committed to cancer patients' quality of life and general well-being and we are delighted to be supporting this educational event. We support the work of The Society on Sarcopenia, Cachexia and Wasting Disorders and look forward to hearing from and working with leading experts on how to improve diagnosis and treatment methods for these debilitating conditions, as we continue to strive to improve the lives of patients living with cancer worldwide."